Strand Therapeutics, a Boston-based biotech company, has successfully raised $153 million in its second-round financing. This significant funding infusion is earmarked to support the progression of its programmable mRNA therapies through clinical trials. Notably, the company’s lead candidate, STX-001, has demonstrated promising results in phase 1 trials. STX-001, an LNP-encapsulated mRNA expressing IL-12, has shown anti-tumor activity in patients with solid tumors, including melanoma, that were unresponsive to existing cancer immunotherapies.
At the recent ASCO cancer congress, STX-001 exhibited encouraging efficacy and safety profiles when administered as a monotherapy directly into tumors, aiming to trigger innate immunity against cancer cells. Following closely behind STX-001 in Strand’s pipeline is STX-003, a systemically administrable programmable mRNA therapy coding for IL-12, designed as a potential cancer treatment. The Series B financing round, led by Kinnevik and supported by prominent biopharma companies such as Regeneron and Amgen, underscores the industry’s belief in the transformative potential of programmable RNA therapies.
In parallel, Artbio, a radiopharma startup based in Massachusetts, secured $132 million in Series B funding to advance its prostate cancer therapy through phase 2 trials. This company, along with a cohort of emerging biotechs, is pioneering radiotherapies utilizing alpha particle-emitting isotopes to target tumors with reduced off-target effects compared to traditional beta radiation therapies. Artbio’s lead program, AB001, targets PSMA for the treatment of metastatic castration-resistant prostate cancer and is currently undergoing early-stage clinical evaluation.
Minghui Pharma from China also made headlines by raising $131 million in a pre-IPO financing round to support its JAK inhibitor-based ointment for atopic dermatitis and advance clinical trials of candidates like MHB039A, a PD-1/VEGF bispecific antibody under evaluation for non-small cell lung cancer. The company is actively seeking development partners, reflecting the growing interest in bispecific antibodies within immuno-oncology, a rapidly evolving field with multiple promising candidates in the pipeline.
Furthermore, Chai Discovery secured a $70 million Series A financing to enhance its AI-powered drug discovery platform, Chai-2. This platform boasts a high success rate in generating antibody candidates by leveraging target antigen and epitope inputs, offering a novel approach to antibody design. The backing from Menlo Ventures and other investors highlights the industry’s confidence in leveraging AI for accelerating drug discovery processes, underscoring the increasing convergence of technology and life sciences.
Key Takeaways:
– Strand Therapeutics’ successful funding round highlights the industry’s enthusiasm for programmable mRNA therapies, with STX-001 showing promising anti-tumor activity.
– Artbio’s focus on alpha particle-emitting isotopes for radiotherapy underscores the interest in novel approaches to cancer treatment with reduced side effects.
– Minghui Pharma’s financing round emphasizes the growing importance of bispecific antibodies in immuno-oncology, with MHB039A advancing in clinical trials.
– Chai Discovery’s AI-powered drug discovery platform signifies the increasing integration of technology in life sciences R&D, offering innovative solutions for antibody development.
Tags: regulatory, bispecifics, biopharma, biotech
Read more on pharmaphorum.com